An article published in Nature in 2019 described a study in which phosphoproteomics was combined with proteomics, transcriptomics, and whole-genome sequencing to find new therapeutic targets for early-stage hepatocellular carcinoma [41]; this study identified avasimibe, a sterol O-acyltransferase 1 (SOAT1) inhibitor, as a potential personalized treatment for patients. The gene discussed is SOAT1; the disease is hepatocellular carcinoma.